# Clinical Study of UTAA06 Injection in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia

> **NCT05722171** · EARLY_PHASE1 · UNKNOWN · sponsor: **PersonGen BioTherapeutics (Suzhou) Co., Ltd.** · enrollment: 10 (estimated)

## Conditions studied

- Relapsed/Refractory Acute Myeloid Leukemia

## Interventions

- **BIOLOGICAL:** gdT cell injection targeting B7-H3 chimeric antigen receptor

## Key facts

- **NCT ID:** NCT05722171
- **Lead sponsor:** PersonGen BioTherapeutics (Suzhou) Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-12-27
- **Primary completion:** 2023-12-27
- **Final completion:** 2024-12-27
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2023-02-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05722171

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05722171, "Clinical Study of UTAA06 Injection in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05722171. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*